Table 1.
Baseline characteristics of the population, N=363.
| Italian cohort, N=177 | French cohort, N=186 | Total, N=363 | |
|---|---|---|---|
| Age at disease onset, years | 2.1 [1.1; 3.4] | 2.0 [1.2; 3.7] | 2.0 [1.2; 3.5] |
| Female | 64 (36%) | 77 (41%) | 141 (39%) |
| Ethnicity, NA=19 | |||
| European | 142 (80%) | 41 (25%) | 183 (53%) |
| African/Afro-Caribbean | 10 (6%) | 100 (60%) | 110 (32%) |
| Asian | 11 (6%) | 26 (16%) | 37 (11%) |
| Complete KD | 105 (59%) | 122 (66%) | 227 (63%) |
| Modifications of extremities | 106 (60%) | 103 (55%) | 209 (58%) |
| Diffuse exanthema | 139 (79%) | 158 (85%) | 297 (82%) |
| Conjunctival injection | 147 (83%) | 148 (80%) | 295 (81%) |
| Cervical adenitis >1.5 cm | 74 (42%) | 99 (53%) | 173 (48%) |
| Modifications of oral mucosa | 154 (87%) | 162 (87%) | 316 (87%) |
| Delay between disease onset and first-line treatment (days) | 7 [5; 9] | 6 [5; 8] | 7 [5; 8] |
| Initial cardiac complications | 58 (33%) | 53 (28%) | 111 (31%) |
| Coronary artery maximal Z- score ≥2.0 | 54 (31%) | 35 (19%) | 89 (25%) |
| Coronary artery maximal Z-score ≥2.5 | 44 (25%) | 31 (17%) | 75 (21%) |
| Myocarditis | 1 (1%) | 3 (2%) | 4 (1%) |
| Pericarditis | 2 (1%) | 27 (15%) | 29 (8% |
| Need for second-line therapy | 26 (15%) | 31 (17%) | 57 (16%) |
| Persisting fever 48h after the start of the initial IVIG therapy | 27 (15%) | 54 (29%) | 81 (22%) |
Categorical variables are expressed as numbers (percentage), and quantitative variables are expressed as median [interquartile range].